Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||14 Jun 2021||Lorem|
|Mersana’s XMT-1522 Her2+ breast cancer toxicity, efficacy results too early to validate platform but encouraging - experts||19 Jun 2018||Manasi Vaidya|
|Mersana’s Phase I ADC oncology study to enroll 120-140 patients in 2018, work with CRO Novella Clinical Research-CMO||06 Oct 2017||Manasi Vaidya|
|Mersana employs CRO Novella for Phase I ADC breast cancer therapy - CEO||30 Nov 2016||Alissa Fleck|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer